Journal article · 2023 · Open access
OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications
Rheumatology, 62(Supplement_2) · Published 1 April 2023 · DOI 10.1093/rheumatology/kead104.008
In brief
“OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications” is a 2023 journal article by Christopher Stovin and 11 co-authors, published in Rheumatology. OpenAlex counts 2 citations as of 19 November 2026. It is open access: the full text is free to read at Rheumatology.
- Citations
- 2
- Most cited in
- 2023 (1)
- Authors
- 12
Abstract
Background/Aims Concerns have been raised about the risk of malignancy with Janus kinase inhibitors (JAKi) following the ORAL Surveillance study, which reported an increased incidence of malignancy with tofacitinib compared with Tumor Necrosis Factor-α inhibitors (TNFi) in people with rheumatoid arthritis (RA) aged over 50 years who had additional cardiovascular risk factors. Our objective was to estimate the risk of malignancy for all licenced JAKi across disease indications, compared with TNFi, methotrexate (MTX), and placebo. Methods A systematic search of electronic databases (Medline, EMBASE, Cochrane) was performed to identify Phase 2/3/4 RCTs and long-term extension (LTE) studies of JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib) in adults with RA, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease, or atopic dermatitis. Comparators were placebo, MTX, and TNFi. Random-effects meta-analysis was performed to compare malignancy incidence rates between JAKi and comparators. Our primary outcome measure was the incidence of all malignancies including non-melanomatous skin cancers (NMSC). Secondary outcomes were malignancies excluding NMSC, and NMSC only. Results In 62 eligible RCTs and 14 LTE studies, there were 71,767 person-years of exposure to JAKi; 2,680 to placebo; 7,827 to TNFi; and 1,074 to MTX. Comparing JAKi with placebo arms of RCTs, the incidence rate ratio (RR) for all malignancies including NMSC was not significantly different (RR 0.81; 95% CI 0.52 to 1.26; p = 0.36). Similarly, when comparing JAKi with MTX, no significant differences were observed in the incidence of malignancy (RR 0.73; 95% CI 0.33 to 1.61; p = 0.43). Compared with TNFi, however, administration of JAKi was associated with an increased incidence of malignancy (RR 1.54; 95% CI 1.19 to 2.01; p = 0.001). For all analyses, findings were consistent when excluding NMSC, when analysing NMSC only, and when including LTE data. Conclusion In trial settings, JAKi do not associate with an increased risk of malignancy compared with placebo or MTX, but are associated with an increased risk of malignancy relative to TNFi. Disclosure C. Stovin: None. M.D. Russell: Honoraria; Lilly, Galapagos, Biogen, Menarini. Other; Lilly, Pfizer, Janssen, UCB. E. Alveyn: None. O. Adeyemi: None. V. Patel: None. M.A. Adas: None. F. Atzeni: None. K.K.H. Ng: None. A.I. Rutherford: None. S. Norton: None. A.P. Cope: Consultancies; BMS, Abbvie, GSK/Galvini. Grants/research support; BMS. J.B. Galloway: Honoraria; Abbvie, Biovitrum, BMS, Celgene, Chugai, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi, UCB.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Stovin, C., Russell, M., Alveyn, E., Adeyemi, O., Patel, V., Adas, M. A., Atzeni, F., Ng, K. K. H., Rutherford, A. I., Norton, S., Cope, A. P., & Galloway, J. B. (2023). OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications. Rheumatology, 62(Supplement_2). https://doi.org/10.1093/rheumatology/kead104.008
MLA 9
Stovin, Christopher, et al. “OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications.” Rheumatology, vol. 62, no. Supplement_2, 2023. https://doi.org/10.1093/rheumatology/kead104.008.
Chicago
Stovin, Christopher, Mark Russell, Edward Alveyn, Olukemi Adeyemi, Vishit Patel, Maryam A. Adas, Fabiola Atzeni, et al. 2023. “OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications.” Rheumatology 62 (Supplement_2). https://doi.org/10.1093/rheumatology/kead104.008.
Harvard
Stovin, C. et al. (2023) ‘OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications’, Rheumatology, 62(Supplement_2). doi:10.1093/rheumatology/kead104.008.
IEEE
C. Stovin et al., “OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications,” Rheumatology, vol. 62, no. Supplement_2, 2023, doi: 10.1093/rheumatology/kead104.008.
BibTeX
@article{stovin2023inhibitors,
title = {{OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications}},
author = {Stovin, Christopher and Russell, Mark and Alveyn, Edward and Adeyemi, Olukemi and Patel, Vishit and Adas, Maryam A. and Atzeni, Fabiola and Ng, Kenrick K H and Rutherford, Andrew I and Norton, Sam and Cope, Andrew P. and Galloway, James Benjamin},
journal = {Rheumatology},
year = {2023},
volume = {62},
number = {Supplement_2},
doi = {10.1093/rheumatology/kead104.008},
url = {https://doi.org/10.1093/rheumatology/kead104.008}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- cancer risk
- cancer incidence
- tofacitinib
- baricitinib
- upadacitinib
- filgotinib
- peficitinib
- tumor necrosis factor inhibitors
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Stovin, C., Russell, M., Alveyn, E., Adeyemi, O., Patel, V., Adas, M. A., Atzeni, F., Ng, K. K. H., Rutherford, A. I., Norton, S., Cope, A. P., & Galloway, J. B. (2023). OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications. Rheumatology, 62(Supplement_2). https://doi.org/10.1093/rheumatology/kead104.008
How many times has this paper been cited?
2 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Rheumatology: sign in and open the PDF from this page.
Who wrote this paper?
Christopher Stovin, Mark Russell, Edward Alveyn, Olukemi Adeyemi, Vishit Patel, Maryam A. Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P. Cope, James Benjamin Galloway.
What is the DOI of this paper?
10.1093/rheumatology/kead104.008, permanently at https://doi.org/10.1093/rheumatology/kead104.008. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.